Alexion Pharmaceuticals accused of gaming US patent system to block Soliris competition
MLex Summary:Â EmblemHealth filed a US complaint today accusing Alexion Pharmaceuticals of unlawfully delaying the introduction of biosimilar competition for eculizumab, a humanized monoclonal antibody that treats a range of rare blood...To view the full article, register now.
Already a subscriber? Click here to view full article